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METHODS: A total of 114 patients with mPCA, lymph node, osseous or visceral metastases underwent cRP. Surgery related complications (Clavien-Dindo classification) and functional outcome were analysed. Oncologic outcome parameters such as cancer specific & overall survival as well as biochemical and clinical-free survival were evaluated using descriptive statistical analysis.
RESULTS: Mean patient age was 61 (42-69) years. Mean and median follow-up was 39.7 months (7-75) and 47 months (28-96), resp. 93 (81.6%) and 21 (18.4%) patients had low volume and high volume mets, resp.,. 80(70.2%) pts underwent neoadjuvant ADT with LHRH analogues. Surgical approach was open retropubic RP in 104 (92%) pts and 2 (1.8%), 10 (8.8%) and 101 (89.4%) pts underwent no, limited or extended pelvic LAD, resp. Adjuvant therapy was delivered in 99 (86.8%) pts. Pathohistology revealed significant vital PCA in 100% of cases: n¼16 (14.0%) exhibited pT4a, n¼21 (18.4%) had pT2 and the remainder had pT3a/b PCA. Positive lymph nodes or positive surgical margins were identified in 61.6% and 36.8%, resp.. 110 (96.5%) are alive and 66.7% are relapse-free. Continence as defined by the use of 0-1 pad/day was achieved in 68.1% pts whereas 17.7% and 14.1% had mild and severe incontinence, resp. 74 (64.9%) pts did not experience any surgery related complications; 15 (13.1%) pts experienced Clavien Dindo grade IIIb/IV complications and underwent minimally invasive or surgical reintervention. The following parameters were associated with relapse: low versus high volume (32.2% vs 50%, p¼0.03), PSA at cRP < 1ng/ml vs PSA > 4 ng/ml, (18.9% vs 45.6%, p¼ 0.02). The following parameters were associated with the Clavien-Dindo complications IIIb (p<0.05): low vs high volume disease (7.1% vs 32.1%), PSA < 4ng/ml vs PSA > 4 ng/ml (6.1% vs 47.8%) and neoadjuvant vs no neoadjuvant therapy (8.75% vs 24.2%).
CONCLUSIONS: cRP is feasible in men with mPCA independent on the extent of disease with a low rate of significant complications and good functional outcome. About two thirds of the patients remain relapse-free after a median follow-up of close to 4 years. cRP might be an individualized treatment option in the multimodality management of mPCA. Isabel Heidegger*, Saskia Kanzelmeyer, David Pfister, Daniel Porres, Pia Paffenholz, Axel Heidenreich, K€ oln, Germany INTRODUCTION AND OBJECTIVES: RAD is one of the new life prolonging therapeutic aproaches in symptomatic mCRPC prior to or after docetaxel treatment. According to guidelines RAD should be initiated early in the progression of mCRPC and it is not to be used as palliative therapy. We analysed the data of RAD therapy in a large single centre cohort of mCRPC patients with the purpose to explore the guideline compliance.
METHODS: A total of 94 patients with symptomatic mCRPC were retrospectively analyzed. All patients had skeletal metastases and no evidence of visceral metastases. The following data were analyzed: proper pretherapeutic work-up including PSA, Hb, platelets, alk. Phos., VAS, creatinine, ECOG performance status, in-house versus external referals, number of cycles, type of pre-treatment. Oncologic outcome parameters such as cancer specific & overall survival as well as biochemical and clinical-free survival were evaluated using descriptive statistical analysis.
RESULTS: Mean patient age was 72.9 (52-84) years. 46 (48.9%) pts received prior DOC; 34 (36.2%) were DOC-naive and in 14 (14.9%) pts the status was unknown. Mean PSA was 267,69 (2.5-4710) ng/ml, mean alk.Phosp. was 177,4 (54.5-594) U/l and mean HB was 12.01 (9.8-15.1) g/dl. Required lab values were missing in 22.3% of pts. ECOG performance status was 0,1 and 2 in 45 (47.9%), 14 (14.9%) and 8 (8.5%), resp.; in the remainder no ECOG was documented. Pts received a mean number of 4 (1-6) cycles; 43 (47.8%) pts received 6 cycles whereas 17 (18.9%), 5 (5.6%) and 25 (27.8%) pts received 4, 5, and 3 cycles, resp. Reason for early discontinuation was: disease progression in 12, poor performance status in 10 and bone marrow suppression in 4. All in-house referals but only 21.5% of outside referals received 6 cycles Rad223. After a mean follow-up of 23.2 (3-30) months, 25 (26.6%) are DOD, 63 (67%) pts are alive and in 6 (6.4%) pts the status is unknown. There was a significant difference in survival rates between 3 and 6 cycles with 62.5% vs 81.1% (p < 0.02) as well as between outside and in-house referals (p < 0.02).
CONCLUSIONS: Although RAD is guideline recommended therapy, clinical reality demonstrates that there the treatment is still inappropriately in 50% of the patients with a significant difference between tertiary referal centres and the community. Observed survival differences are most probably due to the low number of cycles which reflect the terminal stage of disease. More information has to be distributed in the community. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e721
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